Health Canada's fast-tracked drug approvals can put public at risk, experts say
Monday, October 8, 2012 - 19:30
in Health & Medicine
Drugs streamed into Health Canada's 180-day priority review process are more likely to be withdrawn from the market or earn a serious safety warning than those that undergo the 300-day standard review, new research shows. After accounting for other variables which may have caused this variation, the study concludes that the difference is likely due to the faster review time missing serious safety issues.